Wockhardt, a pharmaceutical and biotechnology major and its subsidiary has inked an agreement to divest their nutritional business to Danone, one of the fastest-growing food company in the world. Wockhardt has presence in India's nutritional category with Farex, Dexolac, Nusobee and Protinex. However, the company has retained its nutrition manufacturing facility at Jagraon, Punjab. Further, these transactions are subject to customary closing conditions and various approvals including court approval.
Wockhardt continues to be on the growth track and the strategy to consolidate and rationalize all its core operations is showing encouraging results. The company is re-inventing itself by taking fundamentally strong and positive steps with a firm focus on its core human pharmaceutical business.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s , the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
